Supernus PharmaceuticalsLTS:0LB2 +0.82%88 Days Inventory is 330.51 as of Mar. 2026, which is 11% below its 10-year median of 369.72. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $40.98 (Modestly Overvalued). Among 917 Drug Manufacturers companies, Supernus Pharmaceuticals ranks worse than 84.19% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Supernus Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.28.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Supernus Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.41.
Supernus Pharmaceuticals (LTS:0LB2) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Supernus Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Supernus Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Supernus Pharmaceuticals Days Inventory Related Terms
Supernus Pharmaceuticals Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0LB2 vs BCRX, PBH, RGC: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (LTS:0LB2) has a Days Inventory of 330.51 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Supernus Pharmaceuticals and its competitors. This is 11% below median its historical median of 369.72. Over the past decade, Supernus Pharmaceuticals' Days Inventory has ranged from 260.75 to 572.77. According to the industry distribution chart, Supernus Pharmaceuticals ranks #772 out of 917 companies in the Drug Manufacturers industry, placing it in the top 84.2%.
Is Supernus Pharmaceuticals' Days Inventory too high?
Supernus Pharmaceuticals' current Days Inventory of 330.51 is 11% below median its 10-year median of 369.72. Over the past 10 years, this metric has ranged from a low of 260.75 to a high of 572.77. The Drug Manufacturers industry median Days Inventory is 164.48. Supernus Pharmaceuticals' value of 330.51 is 100.9% above this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #772 out of 917 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Days Inventory compare to BCRX and PBH?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #772 out of 917 companies for Days Inventory. This places Supernus Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 164.48. Supernus Pharmaceuticals' value of 330.51 is 100.9% above this benchmark. Historically, Supernus Pharmaceuticals' own Days Inventory has ranged from 260.75 to 572.77 over the past decade. While the company's 10-year median is 369.72 vs. the industry median of 164.48, Supernus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current Days Inventory of 330.51 is 100.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current Days Inventory is 330.51, which is 11% below median its own 10-year median of 369.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.98, compared to a current price of $46.89 — trading 14.4% above its estimated fair value. The current Days Inventory is 330.51, which is 11% below median its 10-year median of 369.72 and 100.9% above the Drug Manufacturers industry median of 164.48. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Days Inventory is 330.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $46.89 is trading 14.4% above its estimated GF Value™ of $40.98.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LTS:0LB2:
Days Inventory: 330.51 (11% below median its 10-year median of 369.72)
GF Value™: $40.98 vs. price of $46.89 (14.4% above fair value)
Industry Position: 100.9% above the Drug Manufacturers median (#772 of 917)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score
Get the complete analysis for LTS:0LB2
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
